The purpose of this FOA is to provide support for applications that propose a novel genome editing clinical trial that includes at least two different diseases, using the same genome editor, route of administration, and delivery system.
Companion FOAs:
RFA-RM-22-014 , U01 Research Project (Cooperative Agreements)
RFA-RM-22-015 , U19 Research Program (Cooperative Agreement)
RFA-RM-22-017 , U24 Resource-Related Research Project (Cooperative Agreements)
Deadlines:
Letter of Intent Due Date(s): New Date - October 7, 2022 (Original Date: June 17, 2022)
Application Due Date: November 10, 2022
RFA-RM-22-016 Expiration Date New Date - November 11, 2022 (Original Date: July 20, 2022)
Application budgets should not exceed $3M direct costs for Y1 (FY2023), $6.5M direct costs per year for Y2 (FY2024) and Y3 (FY2025), or $4M direct costs per year for Y4 (FY2026) and Y5 (FY2027). Application budgets need to reflect the actual needs of the proposed project.
